Apr 04, 2023 / 03:20PM GMT
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Good morning, and thank you for joining us on day 2 of Guggenheim genomic medicines at our Disease Conference. I am Debjit the therapeutic analyst at Guggenheim. My privilege to host Brian Mueller, BioMarin's Executive VP and Chief Financial Officer. Thank you for your time today, Brian.
Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP
Thanks, Debjit. Appreciate you having us.
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Awesome. So before we get started with the Q&A, do you want to spend a minute just walking people through BioMarin now that the company needs any introduction.
Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP
Yes, absolutely. Thanks for the opportunity. I've got some opening remarks. I'd love to share, really appreciate the opportunity to
Biomarin Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot